These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 20971723

  • 1. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
    Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, Han KH, Jung SC, Suh SH.
    Cardiovasc Res; 2011 Feb 01; 89(2):290-9. PubMed ID: 20971723
    [Abstract] [Full Text] [Related]

  • 2. Globotriaosylceramide induces lysosomal degradation of endothelial KCa3.1 in fabry disease.
    Choi S, Kim JA, Na HY, Cho SE, Park S, Jung SC, Suh SH.
    Arterioscler Thromb Vasc Biol; 2014 Jan 01; 34(1):81-9. PubMed ID: 24158513
    [Abstract] [Full Text] [Related]

  • 3. The endothelium at the brink of calamity in storage disease: more than just overloaded with junk?
    de Wit C.
    Cardiovasc Res; 2011 Feb 01; 89(2):258-9. PubMed ID: 21148146
    [No Abstract] [Full Text] [Related]

  • 4. An in vitro model of Fabry disease.
    Shu L, Murphy HS, Cooling L, Shayman JA.
    J Am Soc Nephrol; 2005 Sep 01; 16(9):2636-45. PubMed ID: 16033856
    [Abstract] [Full Text] [Related]

  • 5. Role of calcium-activated potassium channels with small conductance in bradykinin-induced vasodilation of porcine retinal arterioles.
    Dalsgaard T, Kroigaard C, Bek T, Simonsen U.
    Invest Ophthalmol Vis Sci; 2009 Aug 01; 50(8):3819-25. PubMed ID: 19255162
    [Abstract] [Full Text] [Related]

  • 6. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A, Simonetta I, Riolo R, Todaro F, Di Chiara T, Miceli S, Pinto A.
    Int J Mol Sci; 2021 Sep 18; 22(18):. PubMed ID: 34576250
    [Abstract] [Full Text] [Related]

  • 7. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.
    Park JL, Shu L, Shayman JA.
    Am J Physiol Heart Circ Physiol; 2009 Apr 18; 296(4):H1133-40. PubMed ID: 19202000
    [Abstract] [Full Text] [Related]

  • 8. Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel.
    Si H, Heyken WT, Wölfle SE, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing G, Maier T, Gross V, Bader M, de Wit C, Hoyer J, Köhler R.
    Circ Res; 2006 Sep 01; 99(5):537-44. PubMed ID: 16873714
    [Abstract] [Full Text] [Related]

  • 9. Globotriaosylceramide induces endothelial dysfunction in fabry disease.
    Satoh K.
    Arterioscler Thromb Vasc Biol; 2014 Jan 01; 34(1):2-4. PubMed ID: 24335674
    [No Abstract] [Full Text] [Related]

  • 10. Use of intermediate/small conductance calcium-activated potassium-channel activator for endothelial protection.
    Yang Q, Huang JH, Man YB, Yao XQ, He GW.
    J Thorac Cardiovasc Surg; 2011 Feb 01; 141(2):501-10, 510.e1. PubMed ID: 20546794
    [Abstract] [Full Text] [Related]

  • 11. ER stress mediates homocysteine-induced endothelial dysfunction: Modulation of IKCa and SKCa channels.
    Wang XC, Sun WT, Yu CM, Pun SH, Underwood MJ, He GW, Yang Q.
    Atherosclerosis; 2015 Sep 01; 242(1):191-8. PubMed ID: 26204495
    [Abstract] [Full Text] [Related]

  • 12. Molecular basis for globotriaosylceramide regulation and enzyme uptake in immortalized aortic endothelial cells from Fabry mice.
    Meng XL, Day TS, McNeill N, Ashcraft P, Frischmuth T, Cheng SH, Liu ZP, Shen JS, Schiffmann R.
    J Inherit Metab Dis; 2016 May 01; 39(3):447-455. PubMed ID: 26960552
    [Abstract] [Full Text] [Related]

  • 13. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H.
    PLoS One; 2015 May 01; 10(12):e0144958. PubMed ID: 26661087
    [Abstract] [Full Text] [Related]

  • 14. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
    Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC.
    Neurobiol Dis; 2009 Jan 01; 33(1):48-56. PubMed ID: 18848893
    [Abstract] [Full Text] [Related]

  • 15. Functional role of TRPV4-KCa2.3 signaling in vascular endothelial cells in normal and streptozotocin-induced diabetic rats.
    Ma X, Du J, Zhang P, Deng J, Liu J, Lam FF, Li RA, Huang Y, Jin J, Yao X.
    Hypertension; 2013 Jul 01; 62(1):134-9. PubMed ID: 23648706
    [Abstract] [Full Text] [Related]

  • 16. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF, Quinta R, Pereira CS, Sa Miranda MC.
    Mol Genet Metab; 2012 May 01; 106(1):83-91. PubMed ID: 22425450
    [Abstract] [Full Text] [Related]

  • 17. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
    Do HS, Park SW, Im I, Seo D, Yoo HW, Go H, Kim YH, Koh GY, Lee BH, Han YM.
    EBioMedicine; 2020 Feb 01; 52():102633. PubMed ID: 31981984
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Obesity up-regulates intermediate conductance calcium-activated potassium channels and myoendothelial gap junctions to maintain endothelial vasodilator function.
    Chadha PS, Haddock RE, Howitt L, Morris MJ, Murphy TV, Grayson TH, Sandow SL.
    J Pharmacol Exp Ther; 2010 Nov 01; 335(2):284-93. PubMed ID: 20671071
    [Abstract] [Full Text] [Related]

  • 20. Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization.
    Kerem A, Yin J, Kaestle SM, Hoffmann J, Schoene AM, Singh B, Kuppe H, Borst MM, Kuebler WM.
    Circ Res; 2010 Apr 02; 106(6):1103-16. PubMed ID: 20167930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.